GoldenGolden
ViaCyte

ViaCyte

ViaCyte is a biotechnology company using stem cells to create pancreatic beta cell precursors for treating diabetes.

ViaCyte is a biotechnology company using stem cells to create pancreatic beta cell precursors for treating diabetes that is headquartered in San Diego, California and was founded in 1999 by Paul Laikind.

Timeline

May 26, 2020
ViaCyte raises a $27,000,000 series D round from Bain Capital Life Sciences.
March 2020
ViaCyte raises a $32,600,000 series D round from Bain Capital Life Sciences, RA Capital Management, Sanderling Ventures and TPG Capital Asia.
December 2018
ViaCyte raises a $80,000,000 series D round from Bain Capital Ventures and RA Capital Management.
November 2018
ViaCyte raises a $80,000,000 series D round from Bain Capital Life Sciences, RA Capital Management, Sanderling Ventures and Texas Pacific Group.
September 2018
ViaCyte raises a $10,000,000 convertible note from W. L. Gore and Associates.
December 2017
ViaCyte raises a $1,400,000 grant from California Institute for Regenerative Medicine.
July 2016
ViaCyte raises a $3,900,000 grant.
September 2014
ViaCyte raises a $16,600,000 grant from California Institute for Regenerative Medicine.
August 2014
ViaCyte raises a $5,400,000 series C round.
August 2014
ViaCyte raises a $20,000,000 venture round from Johnson & Johnson Innovation.
Page 1 of 2

Funding rounds

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

$10 Million Grant to ViaCyte from Gore Supports Cell-Based Treatment for Diabetes

Beyondtype1

Web

Center for Beta Cell Therapy in Diabetes and ViaCyte Announce Start of European Clinical Trial of Human Stem Cell-derived Implants in Type 1 Diabetes Patients

ViaCyte, Inc.

Web

ViaCyte encapsulated islet cells show survival success in type 1 diabetes trial

Benedict Jephcote

Web

ViaCyte Secures $80 Million Financing to Advance Functional Cures for Insulin-Requiring Diabetes

ViaCyte, Inc.

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Kyle LaHucik
June 9, 2021
FierceBiotech
ViaCyte snagged $45 million in a new tranche of financing to expand on a 2018 series D worth $80 million. The money will fund the biotech's work on two midstage candidates for type 1 diabetes, and it comes just a day after the biotech said its chief scientific officer is leaving.
BioSpace
June 8, 2021
BioSpace
ViaCyte, Inc., a clinical-stage regenerative medicine company focused on developing cell therapies that provide a functional cure for patients with diabetes, announced the appointment of ViaCyte's current Vice President of Translation Research Evert Kroon, PhD, to serve as interim Chief Scientific Officer following the departure of CSO Kevin D'Amour, PhD.
ViaCyte, Inc.
January 27, 2021
www.prnewswire.com:443
/PRNewswire/ -- ViaCyte, Inc., a clinical-stage regenerative medicine company, today announced the appointment of Michael Yang to President and CEO and as a...
BioSpace
May 28, 2020
BioSpace
ViaCyte, Inc. , a privately held regenerative medicine company, announced today that ViaCyte's President and CEO Paul Laikind , Ph.D. is scheduled to present at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020 at 10 a.m. Eastern Time in Track 9. The company recently announced a $27 million financing to advance
FinSMEs
May 26, 2020
FinSMEs
About | Advertise | Contact | Disclaimer | News | The Daily Deal Newsletter FinSMEs.com by FinSMEs is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.